Creative Medical Technology (NASDAQ:CELZ) & Kymera Therapeutics (NASDAQ:KYMR) Head to Head Contrast

Creative Medical Technology (NASDAQ:CELZ) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Creative Medical Technology and Kymera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-63.05%	-60.42%
Kymera Therapeutics	-191.26%	-24.96%	-20.27%

Earnings & Valuation

This table compares Creative Medical Technology and Kymera Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$11,000.00	794.55	-$5.29 million	($3.80)	-1.32
Kymera Therapeutics	$87.56 million	26.17	-$146.96 million	($2.34)	-15.12

Creative Medical Technology has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

1.4% of Creative Medical Technology shares are held by institutional investors. 2.8% of Creative Medical Technology shares are held by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Creative Medical Technology and Kymera Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	0	0	0	0	0.00
Kymera Therapeutics	0	3	10	1	2.86

Kymera Therapeutics has a consensus target price of $55.62, indicating a potential upside of 57.19%. Given Kymera Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Creative Medical Technology.

Risk and Volatility

Creative Medical Technology has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.

Summary

Kymera Therapeutics beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.